Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor agonists

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 7, 1999, Pages 959-967

  Kovacs, T O G ^a   Campbell, D ^a   Richter, J ^b   Haber, M ^c   Jennings, D E ^d   Rose, P ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d TAP Holdings Limited   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE;

ADULT; AGED; AMBLYOPIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; FEMALE; GASTROINTESTINAL POLYPOSIS; HEADACHE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELENA; MOUTH ULCER; MULTICENTER STUDY; MUSCLE HYPERTONIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SKIN DISEASE; SOMNOLENCE; ULCER HEALING; VERTIGO; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DUODENAL ULCER; FEMALE; GASTRIC MUCOSA; GASTRINS; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; RECURRENCE; TREATMENT OUTCOME; UNITED STATES;

EID: 0033063328     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00569.x     Document Type: Article

References (28)

1. Kurata JH. Ulcer epidemiology: an overview and proposed research framework. Gastroenterology 1989; 96(Pt 2 Suppl 2): 569-80.
2. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-9.
3. deKoster E, Kuipers EJ. Reflux and Helicobacter pylori. Curr Op Gastroenterol 1997; 13: 43-7.
4. Bardhan KD, Bianchi PG, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986; 8: 408-13.
5. Legerton CW. Duodenal and gastric ulcer healing rates: a review. Am J Med 1984; 77: 2-7.
6. McFarland RJ, Bateson MC, Green JRB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98: 278-83.
7. Hawkey CJ, Long RG, Bardhan KD, et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut 1993; 34: 1458-62.
8. Penston JG, Wormsley KG. Review article: maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3-29.
9. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger M, Fordtran J, eds. Gastrointestinal Disease: Pathophysiology/Diagnosis/Management. Philadelphia: Saunders, 1993: 580-679.
10. Holt S, Howden CW. Omeprazole: overview and opinion. Dig Dis Sci 1991; 36: 385-93.
11. Nagaya H, Satoh H, Maki Y. Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1989; 252: 1289-95.
12. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993; 7 (Suppl. 1) (4-12): 29-31.
13. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 1994; 106 (Suppl. 4): A172 (Abstract).
14. Müller P, Dammann HG, Leucht U, Simon B. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989; 3: 193-8.
15. Lanza F, Goff J, Snowcroft C, Jennings D, Greski-Rose P. Double-blind comparison of lansoprazole, ranitidine and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994a; 89: 1191-200.
16. Petite JP, Slama JL, Licht H, et al. Comparaison du lansoprazole (30 mg) et de l'omeprazole (20 mg) dans le traitement de l'ulcer duodenal. Esais therapeutiques multicentriques comparatif en double aveugle. Gastroenterol Clin Biol 1993; 17: 334-40.
17. Ekstrom P, Carling L, Unge P, Anker-Hansen O, Sjostedt S, Sellstrom H. Lansoprazole vs omeprazole in active ulcer: a healing study. Gastroenterology 1995; 30: 210-5.
18. Lanza F, Goff J, Silvers D, Jennings D, Greski-Rose P. Lansoprazole for one year prevents recurrence of duodenal ulcer. Gastroenterology 1994b; 106: A122. (Abstract).
19. Tielemans Y, Hakanson R, Sundler F, Willems G. Proliferation of enterochromaflin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology 1989; 96: 723-9.
20. Misawa T, Chijiiwa Y, Imazono Y. Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res 1991; 122: 175-89.
21. Ogoshi K, Kato T, Saito S. Clinical study of AG-1749 (lansoprazole): effects on serum gastrin levels and gastric mucosal ECL cell density. Yakuri Chiryo 1991; 19: 933-46.
22. Eissele R, Brunner G, Fisher B, et al. Evaluation of enterochromaflin-like (ECL) cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology 1993; 104 (Suppl.): A74. (Abstract).
23. Solcia E, Bordi C, Crcutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200.
24. NIH. Consensus Conference Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
25. Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994; 330: 382-6.
26. Brunner G, Arnold R, Hennig U, Fuchs W. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Therap 1993; 7 (Suppl. 1): 51-5.
27. Sharma B, Axelson M, Pounder RE, et al. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1987; 1: 67-76.
28. Karnes WE, Berlin RG, Maxwell V, Sytnik B, Root JK, Walsh JH. Prolonged inhibition of acid secretion causes hypergastrinaemia without altering pH inhibition of gastrin release in humans. Aliment Pharmacol Ther 1990; 4: 443-56.